DDX3X
Overview
Mutations in the DDX3X gene, which encodes an RNA helicase involved in various aspects of RNA metabolism, have significant implications in B-cell lymphomas, including BL, DLBCL, and other related malignancies and are particularly enriched within MYC-translocated tumors and those expressing the dark zone signature (DZsig).1 These mutations are predominantly loss-of-function (LOF) mutations, affecting the helicase domain of the protein. Missense mutations are predominantly found in male patients and rarely in females, hence showing a sex-specific pattern.2
History
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
timeline
title Publication timing
2012-10-04 : Schmitz : BL
2018-04-12 : Schmitz : DLBCL
2019-09-05 : Mottok : PMBL
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
| 1 | high-confidence PMBL/cHL/GZL genemottokIntegrativeGenomicAnalysis2019b? | |
| 1 | high-confidence BL gene3 | |
| 1 | high-confidence DLBCL geneschmitzGeneticsPathogenesisDiffuse2018a? | |
| 2 | Although recurrent, the relevance of mutations in FL is tenuous |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 44.34 |
| BL | Thomas cohort | 48.70 |
| BL | Panea cohort | 39.60 |
| DLBCL | GAMBL genomes | 8.80 |
| DLBCL | Schmitz cohort | 4.68 |
| DLBCL | Reddy cohort | 4.50 |
| DLBCL | Chapuy cohort | 5.56 |
| FL | GAMBL genomes | 2.54 |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | Yes | Yes | 19.270 | 125.826 |
| DLBCL | Yes | No | 3.193 | 8.744 |
| FL | Yes | No | 11.136 | 21.489 |
aSHM regions
| chr_name | hg19_start | hg19_end | region | regulatory_comment |
|---|---|---|---|---|
| chrX | 42800580 | 42804184 | intergenic | NA |
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
DDX3X Expression
References
1.
Ennishi D, Jiang A, Boyle M, Collinge B, Grande
BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P,
Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S,
Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra
MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.
Double-Hit Gene Expression Signature Defines a
Distinct Subgroup of Germinal Center B-Cell-Like
Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019 Jan
20;37(3):190–201. PMCID: PMC6804880
2.
Gong
C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, Screen M,
Usheva Z, Cucco F, Barrans S, Painter D, Zaini NBM, Haupl B, Bornelöv S,
Ruiz De Los Mozos I, Meng W, Zhou P, Blain AE, Forde S, Matthews J, Khim
Tan MG, Burke GAA, Sze SK, Beer P, Burton C, Campbell P, Rand V, Turner
SD, Ule J, Roman E, Tooze R, Oellerich T, Huntly BJ, Turner M, Du MQ,
Samarajiwa SA, Hodson DJ. Sequential inverse
dysregulation of the RNA helicases DDX3X and
DDX3Y facilitates MYC-driven
lymphomagenesis. Molecular Cell. 2021;
3.
Schmitz R, Young RM, Ceribelli M, Jhavar S,
Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell
J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P,
Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E,
Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI,
Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S,
Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.
Burkitt lymphoma pathogenesis and therapeutic targets from structural
and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867


